Antibody-drug conjugates (ADC) against cancer stem-like cells (CSC) - Is there still room for optimism? by F. Marcucci et al.
REVIEW
published: 29 March 2019
doi: 10.3389/fonc.2019.00167
Frontiers in Oncology | www.frontiersin.org 1 March 2019 | Volume 9 | Article 167
Edited by:
Cyril Corbet,
Catholic University of Louvain,
Belgium
Reviewed by:
Ron Firestein,
Hudson Institute of Medical Research,
Australia
Cynthia Guidi,
ImmunoGen, United States
*Correspondence:
Fabrizio Marcucci
fabmarcu@gmail.com.
Specialty section:
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Oncology
Received: 27 December 2018
Accepted: 25 February 2019
Published: 29 March 2019
Citation:
Marcucci F, Caserta CA, Romeo E
and Rumio C (2019) Antibody-Drug
Conjugates (ADC) Against Cancer
Stem-Like Cells (CSC)—Is There Still
Room for Optimism?
Front. Oncol. 9:167.
doi: 10.3389/fonc.2019.00167
Antibody-Drug Conjugates (ADC)
Against Cancer Stem-Like Cells
(CSC)—Is There Still Room for
Optimism?
Fabrizio Marcucci 1*, Carmelo Antonio Caserta 2, Elisabetta Romeo 2 and Cristiano Rumio 1
1Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy, 2 Fondazione per la Medicina
Solidale, Reggio Calabria, Italy
Cancer stem-like cells (CSC) represent a subpopulation of tumor cells with peculiar
functionalities that distinguish them from the bulk of tumor cells, most notably their
tumor-initiating potential and drug resistance. Given these properties, it appears logical
that CSCs have become an important target for many pharma companies. Antibody-drug
conjugates (ADC) have emerged over the last decade as one of the most promising
new tools for the selective ablation of tumor cells. Three ADCs have already received
regulatory approval and many others are in different phases of clinical development.
Not surprisingly, also a considerable number of anti-CSC ADCs have been described
in the literature and some of these have entered clinical development. Several of these
ADCs, however, have yielded disappointing results in clinical studies. This is similar to
the results obtained with other anti-CSC drug candidates, including native antibodies,
that have been investigated in the clinic. In this article we review the anti-CSC ADCs
that have been described in the literature and, in the following, we discuss reasons
that may underlie the failures in clinical trials that have been observed. Possible reasons
relate to the biology of CSCs themselves, including their heterogeneity, the lack of strictly
CSC-specific markers, and the capacity to interconvert between CSCs and non-CSCs;
second, inherent limitations of some classes of cytotoxins that have been used for the
construction of ADCs; third, the inadequacy of animal models in predicting efficacy in
humans. We conclude suggesting some possibilities to address these limitations.
Keywords: cancer stem cell, epithelial-mesenchymal transition, resistance, antibody-drug conjugate, resting,
proliferating
CANCER STEM-LIKE CELLS (CSC), A TUMOR CELL
SUBPOPULATION WITH PECULIAR PROPERTIES
CSCs are carcinoma cells that self-renew and give rise to differentiated tumor cells. CSCs by
themselves, however, can arise from differentiated tumor cells when these cells undergo an
epithelial-mesenchymal transition (EMT) (1). EMT involves changes that lead to loss of cell-cell
adhesion and cell polarity, with acquisition of migratory and invasive properties (2). EMT
encompasses a continuum of states from a fully epithelial to a fully mesenchymal phenotype,
passing through intermediate, hybrid states (3). Interestingly, it has recently been shown that
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acquisition of tumor-initiating potential is one of the earliest
functions gained during EMT, while other functions, like
invasiveness and metastatic potential are acquired during later
stages (4). These results reinforce the close relationship between
EMT and CSCs (1).
In addition to their tumor-initiating potential, CSCs possess
also other functions that they share with EMT tumor cells, most
notably drug resistance (5). Drug resistance implies that tumor
cells survive drug treatment and become enriched in the tumor
cell population. In fact, one key assay to ascertain the in vivo
efficacy of anti-CSC compounds is to test the number of tumor
cells that are required in order to initiate tumor growth in animal
models before and after drug treatment (6).
Considerable efforts have been devoted to the phenotypic
characterization of CSCs, in particular the identification of
markers that distinguish CSCs from normal stem cells and the
bulk of differentiated tumor cells. Overall, it has been difficult to
define CSCs on the basis of their phenotypic profile (5). Thus,
a large number of cell surface molecules that are expressed on
CSCs have been identified; CD44, CD47, CD33, CD133, CXC
chemokine receptor (CXCR) 4, and CD26 are some of these
markers. Most of them, however, are not CSC-specific and in
some cases are even ubiquitously expressed (e.g., CD44, CD47)
(7). Some markers have a more restricted expression and/or are
overexpressed on CSCs; these have been used as targets for ADCs,
as will be discussed in the following.
The plasticity of CSCs is reflected also by the large number
of signaling pathways that are involved in the induction and
maintenance of CSCs. Given the functional relationship between
CSCs and normal stem cells, the role of signaling pathways
involved in the physiology of normal stem cells, such as WNT,
Notch, and Hedgehog (Hh), has been investigated with particular
attention (8).
Eventually, also post-transcriptional regulation contributes to
the homeostasis and functions of CSCs. These include RNA
modifications, RNA-binding proteins, mircoRNAs and long non-
coding RNAs (9).
As regards the generation of CSCs from differentiated
tumor cells, similarly to cells that undergo an EMT, tumor-
initiating potential can be acquired when one of three different
events occur. First, in response to stressors from the tumor
microenvironment like hypoxia, low pH, immune responses,
mechanical stress, and antitumor drugs (10, 11). Second,
stressor-promoted epigenetic changes that induce heritable
effects allowing retention of the mesenchymal state even when
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mesenchymal transition; Eph, Ephrin receptor; FLT3, fms-like tyrosine kinase 3;
GO, gemtuzumab ozogamicin; HER2, human epidermal growth factor receptor 2;
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the stressors are no longer present (12, 13). Third, stimulus-
independent activation of signaling pathways, owing to activating
mutations or overexpression of pathway components (14, 15).
Intuitively, these events are not mutually exclusive and may
differ quantitatively and qualitatively in different tumors and,
over time, even within the same tumor. Moreover, some of these
events (e.g., stressor-induced responses) can be reversible and,
consequently, CSCs can revert back to a differentiated phenotype,
as already referred to above. Vice versa, tumor cells that have
regained an epithelial and a non-CSC phenotype can undergo
a de novo switch toward a more mesenchymal tumor-initiating
phenotype, even after drug-induced depletion of CSCs. As such,
depletion of CSCs is by no means a conclusive effect but, rather, a
transient elimination of tumor cells engaged in the replenishment
of a tumor cell population of epithelial phenotype.
ANTIBODY-DRUG CONJUGATES (ADC),
TOOLS FOR THE SELECTIVE
ELIMINATION OF TUMOR CELLS
ADCs comprise a monoclonal antibody (mAb) against a tumor-
associated antigen, a covalent linker, and a cytotoxic payload (16).
Figure 1 gives a schematic view of an ADC and its individual
components as will be discussed in the following. In most cases,
ADCs are internalized upon binding to the cognate antigen and
the cytotoxic payload is released, causing cell death. The targeted
delivery of cytotoxins to tumor cells allows for the maximum
efficacy and minimal toxicity.
The mAb should recognize an antigen expressed on the
largest possible fraction of tumor cells and the smallest possible
fraction of normal cells (17). With the exception of hematological
malignancies, there is no known antigen that is homogeneously
expressed on all tumor cells because the tumor cell population
is, in itself, heterogeneous and composed, to varying degrees,
of antigen-positive or strongly positive (preferably the vast
majority) and antigen-negative or weakly positive tumor cells.
Incidentally, the existence of phenotypic tumor cell heterogeneity
justifies the aim of generating anti-CSC ADCs, because this rests
on the assumption that CSCs display an antigenic profile that
differs qualitatively and/or quantitatively from that of non-CSCs
and, thus, may escape cytotoxicity induced by ADCs that target
non-CSCs. MAbs that are currently used for the engineering of
ADCs are of human origin or are humanized murine antibodies
(18, 19) in order to minimize antigenicity and the induction of
anti-drug antibodies.
The second component, the linker, is important for the
stability of the ADC. It should be sufficiently stable to negate
systemic release of the cytotoxic payload, but sufficiently labile
to allow intracellular release, in most cases within the lysosomal
compartment. Dipeptide linkers like valine-citrulline are typical
examples of linkers that are cleaved with good selectivity
within the lysosomal compartment (20). However, for some
ADCs also non-cleavable linkers are used and, in this case, the
cytotoxic payload is released as an amino acid conjugate upon
degradation of the antibody. These linkers can be used if the
drug-linker-amino acid residue conjugate retains drug activity
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FIGURE 1 | A Schematic View of ADCs and its Individual Components. The mAb targets a tumor-associated antigen, in the present case an antigen that is
preferentially expressed on CSCs. The linker may be cleavable (e.g., acid-sensitive or dipeptide) or non-cleavable (e.g., maleimidocaproyl). The cytotoxin may be an
antimitotic drug, active only on proliferating cells or a DNA-binding drug, active also on quiescent cells. Moreover, the cytotoxin may be hydrophilic and act only within
the internalizing cell or it may be hydrophobic and act also on nearby cells, whether antigen-positive or –negative (so-called bystander effect). ADC, antibody-drug
conjugate; CSC, cancer stem-like cell; mAb, monoclonal antibody.
(21). Ado-trastuzumab emtansine is an example of an ADC with
a non-cleavable linker yielding a lysine-linker-cytotoxic (DM1)
complex (22).
Cytotoxins used for ADC synthesis are highly potent
because of the limited number of payloads that each individual
antibody molecule can carry. Most ADC payloads belong to
two mechanistic classes. The first are antimitotic, tubulin-
binding cytotoxins like auristatins and maytansines. The
second are DNA-binding, cell cycle-independent cytotoxins like
calicheamicins and pyrrolobenzodiazepines (PBD).
Once released, a cytotoxin may be cell-impermeable [e.g.,
more hydrophilic cytotoxins like monomethyl auristatin (MMA)
F] and exert its cytotoxic effect exclusively on a single cell,
or it may penetrate the cell membrane and exert bystander
killing also on nearby cells (e.g., more lipophilic cytotoxins like
MMAE) (23), whether or not these cells are positive for the target
antigen. This potential advantage of cell-permeable cytotoxins
must be weighed against the possibility of enhanced systemic
toxicity due to back-flow of the liberated cytotoxin into the
systemic circulation.
Until recently, most ADCs were generated by random
conjugation of the linker to available cysteine or lysine residues
on the antibody. This approach leads to ADC mixtures
with different drug-antibody ratios (DAR) with the individual
components having distinct properties that may lead to
suboptimal in vivo efficacy of the final mixture. In recent years,
site-specific conjugation methods have been developed, which
yield ADCs with defined DARs. These ADCs have been shown
to possess larger therapeutic windows and to be better tolerated
than randomly-conjugated ADCs (24, 25).
An important question to answer in the present context
is as to why an ADC should be preferred over a native mAb
as an anti-CSC agent. The question is not trivial since also
native antibodies are endowed with cytotoxic potential. In
fact, mechanisms like antibody-dependent cellular cytotoxicity,
complement-dependent cytotoxicity or antibody-dependent
cellular phagocytosis contribute, to varying degrees, to the
efficacy of an antitumor mAb (26). The answer lies in the
greater antitumor efficacy that ADCs have demonstrated in
vivo compared to native, equivalent mAbs (27) and the efficacy
that ADCs, like ado-trastuzumab emtansine (T-DM1), have
shown in tumors that were ab initio unresponsive or had become
unresponsive to the native equivalent (trastuzumab) (28). It is to
note, however, that the cytotoxic potential of the native mAb has
been shown to contribute to the overall efficacy of ADCs (29).
ANTI-CSC ADCS THAT HAVE BEEN
DESCRIBED IN THE LITERATURE
In the following we will discuss individual anti-CSC ADCs that
have been reported in the scientific literature. In some instances,
more than one ADC has been described against an individual
target and we will briefly address the properties of each of
these conjugates. We will first discuss those ADCs that target
markers expressed on CSCs. In a following section we will discuss
antitumor ADCs that were shown to have anti-CSC activity at a
later stage.
ADCs Against Markers Expressed on CSC
Anti-delta-like Ligand (DLL) 3 ADC
This target is of particular interest in these days, because the
development of an ADC against DLL3, rovalpituzumab tesirine,
which had reached phase III clinical studies, has failed to show
benefit in third-line small-cell lung cancer (SCLC) (30).
Rovalpituzumab tesirine had been constructed for the
targeting of CSCs of high-grade pulmonary endocrine
tumors (31). These tumors include SCLC and large cell
neuroendocrine carcinoma, highly malignant neoplasms with
few and inefficacious therapeutic options (32). CSCs of SCLC are
thought to arise from normal pulmonary neuroendocrine cells,
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the portion of the diffuse neuroendocrine system found in the
respiratory epithelium.
DLL3 is a ligand of the mammalian Notch family that localizes
to the Golgi apparatus without being able to activate Notch
signaling like other Notch ligands. Rather, DLL3 appears to
inhibit Notch pathway activation by interacting with Notch and
the Notch ligand DLL1, thereby preventing their localization to
the cell surface (33). Notch activation in neuroendocrine tumors
has been shown to suppress tumor growth (34). Expression data
showed that DLL3 mRNA is overexpressed in primary SCLC
tumors, SCLC patient-derived xenografts (PDX), conventional
SCLC cell lines, and large-cell neuroendocrine carcinoma PDXs,
whereas mRNA expression in normal tissues appears limited
primarily to the brain (31). Moreover, in contrast to normal
cells, DLL3 was detectable at the surface of neuroendocrine
tumor cells.
On the basis of these observations, DLL3 was selected as a
target for the construction of an ADC. The ADC, SC16LD6.5
(later rovalpituzumab tesirine) is composed of a humanized
anti-DLL3 mAb, conjugated to a PBD dimer. The payload
was conjugated to cysteine residues on the mAb via a valine-
alanine dipeptide, with a mean DAR of 2. SC16LD6.5 induced
durable tumor regression in multiple PDX models after a
single course of therapy and in a manner independent of their
sensitivity to standard-of-care (SOC) chemotherapy. Lack of
tumor recurrence was shown being due to depletion of DLL3+
CSCs. In contrast, SOC chemotherapy did not reduce the
frequency of CSCs nor provided durable responses in spite of
efficacious tumor cell debulking. DLL3, however, was not CSC-
specific since its expression was seen throughout the tumor, with
most cells expressing it to some degree. For this reason, the
rapid tumor debulking seen with SC16LD6.5 was likely due to
DLL3 expression on most tumor cells. Eventually, SC16LD6.5
was efficacious also in a chemorefractory tumormodel suggesting
that patients with tumors resistant to SOC will be responsive to
this conjugate. Of note, administration of the unconjugated anti-
DLL3mAb, even at high doses, or the equivalent dose of free PBD
dimer had little or no effect on tumor growth, thereby supporting
the superiority of the antitumor effects of the ADC.
Rovalpituzumab tesirine has entered numerous clinical
studies and has progressed until phase III in patients with
advanced SCLC after disease progression following SOC
chemotherapy protocols (Table 1). Other clinical trials are
earlier stage in SCLC alone (NCT02674568, NCT02819999,
NCT03319940, NCT02874664) or in SCLC and other advanced
solid tumors expressing cell surface DLL3 (NCT02709889). As
referred to in the beginning of this section, rovalpituzumab
tesirine failed to show benefit in one of the SCLC studies.
Anti-protein Tyrosine Kinase 7 (PTK7) ADC
PTK7 has been identified as a CSCmarker and potential target for
ADCs (35). It is a conserved member of the pseudokinase family
of receptor protein tyrosine kinases. The lack of kinase activity
is the consequence of substitutions at residues in the kinase
domain. Oncogenic functions of PTK7, including resistance to
chemotherapy, have been reported for various carcinomas and
acute myeloid leukemia (AML) (49). PTK7 was shown to be
overexpressed in tumors vs. normal tissues, and enriched in CSCs
of different tumor types. PTK7 expression within each tumor is
heterogeneous, and the extent of heterogeneity varies from tumor
to tumor. PTK7 staining was also observed in some normal
tissues, including esophagus, urinary bladder, kidney, mammary
gland, lung, ovary, uterus, and digestive tract (35). The expression
profile of PTK7 prompted the generation an anti-PTK7 ADC
(35). The choice of an ADC was also dictated by the lack of
catalytic function of PTK7, making it an unsuitable target for
inhibitor antibodies or small molecules.
The anti-PTK7 ADC that was constructed, PF-06647020,
comprises a humanized anti-PTK7 mAb, a cleavable dipeptide
(valine-citrulline) linker, and Aur0101, an auristatin microtubule
inhibitor. PF-06647020 induced sustained regressions in PDX
models and reduced the frequency of CSCs. In addition to
CSC depletion, PF-06647020 may also have additional antitumor
mechanisms of action, including angiogenesis inhibition and
stimulation of immune cells. These activities may be facilitated
by the bystander effect of the membrane-permeable hydrophobic
auristatin payload. Importantly, despite the expression of PTK7
in certain normal tissues, no target-dependent toxicities were
observed in monkeys, possibly because microtubule inhibitors
require high antigen expression and actively cycling cells to exert
a cytotoxic effect (50).
Two clinical studies with PTK7-ADC/PF-06647020 are
currently ongoing: a safety study of the combination gedatolisib
plus PF-06647020 for metastatic triple-negative breast cancer
(TNBC) (NCT03243331), and a phase I study of PF-06647020 in
adult patients with advanced solid tumors (NCT02222922).
Anti-Eph-A4 (EFNA4) ADC
Ephrin receptors (Eph) are the largest family of receptor tyrosine
kinases in the human genome and, together with their ligands,
have been implicated in the development of breast cancer.
Consequently, numerous therapeutics, mostly tyrosine kinase
inhibitors are being actively developed to inhibit the function of
this ligand/receptor family. A significant limitation of currently
developed drug candidates is represented by the vast functional
redundancy of this family, while general inhibition of ephrin
receptors is toxic (51). In contrast, ADCs prescind from the
functional role of ligand/receptor pairs and exert cytotoxic effects
only on those target-expressing cells that internalize them.
MRNA expression of one of these receptors, EFNA4, was
found to be elevated in CSCs compared to non-tumorigenic
cells and normal tissues. Protein analysis of normal organs,
primary breast tumor specimens and TNBC PDX tumor models
demonstrated that EFNA4 was elevated in TNBC vs. normal
tissues and other subtypes of breast cancer (36). This expression
pattern suggested the possibility of targeting EFNA4 with
an ADC.
In order to target EFNA4, the ADC PF-06647263 was
constructed. It is composed of an anti-EFNA4-specific,
humanized mAb, a hydrazone linker and a calicheamicin
payload. Conjugation was to lysine residues of the antibody and
yielded an average DAR of 4.6. Calicheamicin was selected as
payload because of the presence, within the CSC population, of
quiescent as well as cycling cells (67). Quiescent cells are resistant
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TABLE 1 | Anti-CSC ADCs.
Target: ADC name Linker:
Cleavable/uncleavable
Cytotoxin:
Antimitotic, DNA
binder
Developmental stage
Stage, ClinicalTrials.gov identifiers, results if
available
References
ADCs AGAINST MARKERS EXPRESSED ON CSC
DLL3: rovalpituzumab
tesirine
Cleavable (dipeptide) DNA binder (PBD
dimer)
Phase III, NCT03061812, vs. topotecan in DLL3+
advanced or metastatic SCLC at first disease
progression after platinum chemotherapy
Phase III, NCT03334487, evaluating the safety for
third-line and later treatment of relapsed or refractory
SCLC
Phase II, NCT02674568, as third-line and later treatment
for subjects with relapsed or refractory DLL3+ SCLC
Other phase I/II studies in patients with DLL3+ SCLC
(NCT02819999, NCT02874664) or SCLC and other
solid tumors (NCT02709889)
(30, 31)
Protein tyrosine kinase
7 (PTK7):
PF-06647020
Cleavable (dipeptide) Antimitotic (Aur0101) Safety study, NCT03243331: with gedatolisib in TNBC
Phase I, NCT02222922: in adult patients with advanced
solid tumors
(35)
Ephrin-A4 (EFNA4):
PF-06647263
Cleavable (hydrazone) DNA binder
(calicheamicin)
Phase I, NCT02078752: in patients with advanced solid
tumors
(36)
IL-3 receptor α chain
(CD123): SGN-123
Cleavable (dipeptide) DNA binder (PBD
dimer)
Phase I, NCT02848248, in AML patients. Study
terminated, presumably no longer in active development.
(37)
5T4: PF-06263507 Non-cleavable
(maleimidocaproyl)
Antimitotic (MMAF) Phase I, NCT01891669, no objective responses were
observed
(38, 39)
5T4: MEDI-0641 Cleavable (dipeptide) DNA binder (PBD
dimer)
Antimitotic (tubulysin)
Not reported (40, 41)
5T4: H6-DM4 Cleavable (SPDB) Antimitotic (DM4) Not reported (42)
LGR5 Cleavable (dipeptide)
Non-cleavable
(malemidopropionyl)
Antimitotic (MMAE)
Antimitotic (MMAE)
Not reported
Not reported
(43)
LGR5 Cleavable (dipeptide)
Cleavable (acid-
sensitive)
Antimitotic (MMAE)
DNA binder
(PNU159682)
Not reported
Not reported
(44)
ANTITUMOR ADCs THAT WERE SHOWN TO HAVE ANTI-CSC ACTIVITY AT A LATER STAGE
HER2: T-DM1,
ado-trastuzumab
emtansine
Non-cleavable Anti-mitotic (DM1) FDA-approved for the treatment of HER2-positive
metastatic breast cancer.
(45)
CD33: gemtuzumab
ozogamicin
Cleavable (hydrazone) DNA binder
(calicheamicin)
FDA approval in 2000 for the treatment of AML.
Voluntarily withdrawn in 2010 due to safety concerns.
Recently reapproved.
(46)
NCAM (CD56):
lovortuzumab
mertansine
Cleavable Anti-mitotic (DM1) It was in development as antitumor agent, not
specifically as anti-CSC agent. Development now halted
due to disappointing results in lung cancer patients
(47, 48)
ADC, antibody-drug conjugate; AML, acute myeloid leukemia; CSC, cancer stem-like cells; DLL3, Delta-like ligand 3; EFNA4, Ephrin-A4; FDA, Food and Drug administration; HER2,
human epidermal growth factor receptor 2; LGR5, leucine-rich repeat-containing, G protein-coupled receptor 5; MMAE, monomethyl auristatin E; NCAM, neural cell-adhesion molecule;
PBD, pyrrolobenzodiazepine; PTK7, protein tyrosine kinase 7; SCLC, small-cell lung cancer.
to antimitotic, cell-cycle-dependent microtubule inhibitors like
auristatins and maytansines. Calicheamicins, on the other hand,
are DNA-binding drugs that are cytotoxic independently of the
cell cycle status.
PF-06647263 induced significant tumor regression in TNBC
xenografts. The most robust responses were observed in non-
claudin low TNBCs, with complete responses observed in
several cases. This result correlates with the increased EFNA4
expression observed in this breast cancer subtype. EFNA4
expression was also elevated on a subset of ovarian cancers and
PF-06647263 induced sustained regression also on xenografts of
these tumors.
A phase I study has been performed with PF-06647263 in
patients with advanced solid tumors (NCT02078752). The study
has been completed and no other studies are currently ongoing.
Of note, also another anti-Eph ADC has been reported in
the literature (MEDI-547) (52). This ADC targets EFNA A2 and
showed substantial activity in in vivo models of endometrial
carcinoma. However, no evidence was brought that this ADC
has some preferential activity on CSCs. A clinical study with this
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ADC has evidenced early and serious adverse events and has led
to the discontinuation of its development (53).
An Anti-CD123 ADC
CD123 is the α chain of the interleukin (IL)-3 receptor. Upon
binding of IL-3, CD123 heterodimerizes with the β subunit of the
IL-3 receptor and gives rise to intracellular signals promoting cell
survival and proliferation (54). CD123 is expressed on the surface
of myeloblasts and leukemia stem cells (LSC, the equivalent of
CSCs for hematologic malignancies) of AML patients (55, 56).
These cells have been associated with chemotherapy resistance,
persistence of minimal residue disease and unfavorable prognosis
(57, 58). CD123 is expressed at very low levels or is absent from
normal hematopoietic stem cells, thereby offering the possibility
of targeting AML stem cells while sparing normal stem cells (59).
The generation and preclinical investigation of an anti-
CD123 ADC has recently been reported (37). This ADC, dubbed
SGN-CD123A, is composed of a humanized anti-CD123 mAb
with engineered cysteines for site-specific conjugation, a valine-
alanine dipeptide linker and a PBD dimer payload. In vitro,
SGN-CD123A had potent cytotoxic effects on most CD123+
AML cells lines and primary samples from AML patients. SGN-
CD123A was highly active in various leukemia models and led
to eradication in a disseminated AML model. SGN-CD123A
was also tested in combination with the fms-like tyrosine
kinase 3 (FLT3) inhibitor quizartinib. FLT3 inhibitors are in
development for FLT3-mutated AML patients, but responding
patients invariably develop resistance. SGN-CD123A enhanced
the activity of quizartinib in FLT3-mutated xenograft models.
A phase I clinical trial has been performed with SGN-CD123A
in AML patients (NCT02848248). This study, however, has
been terminated, and on the company’s website this product is
not mentioned.
Anti-5T4 ADCs
5T4, or trophoblast glycoprotein, is a 72-kDa, N-glycosylated
transmembrane protein. The extracellular domain contains
leucine-rich repeats, which are commonly associated with
protein-protein interactions. 5T4 is expressed in normal
progenitor cells during embryonic development where it
functions in EMT and cell migration (60). It is an oncofetal
antigen with high expression in many types of carcinomas and
low expression in normal tissues. 5T4 has been found to be
overexpressed in CSCs in non-small cell lung cancer (NSCLC)
and other cancers (61) compared to differentiated tumor cells.
5T4-overexpressing cells also show increased expression of EMT
markers and have increased tumor-initiating potential (61).
Moreover, as expected for EMT tumor cells and CSCs, 5T4
overexpression is associated with advanced-stage disease, drug
resistance and worse prognosis in several solid tumors (62–64).
Several ADCs targeting 5T4 have been described in the
literature. The first, PF-06263507, comprises a humanized anti-
5T4 mAb linked to the tubulin inhibitor MMAF via a non-
cleavable maleimidocaproyl linker (38). MMAF preferentially
acts on proliferating cells due to its antimitotic mechanism of
action. This ADC was very potent in several tumor models
inducing long-term regressions with low doses. In a NSCLC
xenograft model the ADC reduced CSC frequency. In safety
studies in primates it was safe and had a half-life of 5 days.
In the following, PF-06263507 was tested in combination with
the dual phosphoinositide 3-kinase (PI3K)/mechanistic target of
rapamycin (mTOR) catalytic site inhibitor PF-384 or taxanes
(65). In vitro, PF-06263507 or untargeted auristatins displayed
strong synergistic or additive activity when combined with PF-
384 or taxanes, respectively. These synergistic/additive activities
were not due to the individual components of the combination
acting on different tumor cell subpopulations (e.g., CSC and non-
CSC cells) but, rather, to amplification of the effects of this ADC
on translational components by PF-384 or the simultaneous
binding of MMAF and taxanes to distinct binding sites on
microtubules, respectively. In human breast and lung cancer
xenografts, combination therapy with PF-06263507 + PF-384
or PF-06263507 + paclitaxel yielded enhanced antitumor effects
with longer survival as compared with monotherapies.
The potential of PF-06263507 for the treatment of
hematological malignancies was also investigated (66), given the
finding that 5T4 was overexpressed on minimal residual acute
lymphoblastic leukemia (ALL) cells. PF-06263507 significantly
improved survival in mice engrafted with 5T4+ patient-derived
ALL cells, and even more so in combination with chemotherapy
or dexamethasone.
PF-06263507 has been investigated in a phase I clinical trial
(NCT01891669) and the results of this study, where no objective
responses were observed, have been reported (39).
In another approach, anti-5T4 ADCs were constructed by
site-specifically conjugating a human anti-5T4 mAb via a
valine-alanine dipeptide linker with payloads having different
mechanisms of action: a PBD dimer or the microtubule
destabilizing tubulysin (40). In vivo experiments in xenograft
models of different carcinoma types showed that the ADC
conjugated with a PBD payload, MEDI-0641, elicited more
durable antitumor responses and inhibited more potently the
growth of 5T4+ CSCs in vivo than the tubulysin conjugate.
This result is consistent with the knowledge that CSCs comprise
subpopulations of proliferating and quiescent cells (67) and that
a DNA binder like a PBD is cytotoxic also on quiescent cells,
while a tubulin binder like tubulysin acts only on the proliferating
CSC subpopulation. Moreover, MEDI-0641 was cytotoxic on
both CSC and non-CSC tumor cells, leading to depletion of
both compartments. This result implies that 5T4 is pan-tumor
cell marker, whether or not overexpressed by CSCs. In rats,
MEDI-0641 had excellent in vivo stability and an acceptable
safety profile.
MEDI-0641 was then tested on cells and xenografts of
head and neck squamous cell carcinoma (HNSCC) (41). In
vitro, it caused a significant depletion of CSCs. In vivo,
in three patient-derived xenograft models of HNSCC, a
single administration of MEDI-0641 caused long-lasting tumor
regression, which was likely due to depletion of both CSCs and
non-CSCs. In the three models, MEDI-0641 caused either a
complete elimination of tumor-initiating cells or a significant
reduction. Moreover, a single dose of MEDI-0641 prevented
tumor recurrence when used in a neoadjuvant setting prior
to surgery.
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MEDI-0641 does not seem to have yet entered clinical
development as it is not mentioned neither under
clinicaltrials.gov nor in the company’s website.
A third anti-5T4 ADC has been described very recently
(42). This ADC, H6-DM4, is composed of a chimeric anti-5T4
mAb linked to an antimitotic cytotoxin, the maytansinoid DM4,
through a cleavable N-succinimidyl 4-(2-pyridylothio)butyrate
(SPDB) linker sensitive to intracellular reducing conditions with
liberation of a lipophilic adduct, S-methyl-DM4, that can exert
a bystander effect. H6-DM4 was cytotoxic against a panel of
gastrointestinal cancer cell lines, including colorectal CSCs and
colorectal cancer cells resistant to platinum compounds. CSCs
were found to express higher levels of 5T4 than non-CSCs. 5T4
eradicated established gastrointestinal tumor xenografts in the
low mg/kg range without observable toxicity. Tumor cell lines
expressing higher levels of 5T4 were more sensitive to the effects
of the conjugate in vivo, suggesting that the expression level of
5T4 could represent a predictive marker for patient selection.
Anti-leucine-rich Repeat-Containing, G
Protein-Coupled Receptor 5 (LGR5) ADCs
LGR5 is a marker of adult stem cells in several epithelial
tissues. In particular, LGR5+ crypt cells in the gastrointestinal
tract give rise to all differentiated cell types within intestinal
epithelia, suggesting that it represents the stem cell of the small
intestine and colon (68). LGR5 is overexpressed and gives rise
to multiple cell types within gastrointestinal tumors (68, 69).
These observations suggest a close relationship between normal
adult gastrointestinal stem cells and CSCs of gastrointestinal
tumors. LGR5 overexpression correlates with higher incidence
of metastasis, drug resistance, and poor patient survival (70, 71).
Given its overexpression and rapid, constitutive internalization
independently of ligand binding (72), LGR5 was considered a
good target for ADCs.
Two ADCs were constructed by conjugating an anti-LGR5
mAb to the membrane-permeable, antimitotic agent MMAE
via a cleavable valine-citrulline linker or a non-cleavable
malemidopropionyl linker (43). Both ADCs bound LGR5 with
similar affinity and were rapidly internalized by gastrointestinal
cancer cells. Cytotoxicity was induced in LGR5-overexpressing
cancer cells, but not in LGR5-negative cells or cell lines
where LGR5 had been knocked down. However, the ADC
with the cleavable linker was 10- to 20-fold more potent at
killing these cells, probably due to a bystander effect (73).
In fact, the ADC with the non-cleavable linker gives rise to
charged metabolites (e.g., amino acid-linker-cytotoxin) that are
membrane-impermeable. The ADC with the cleavable linker
eradicated tumors and prevented recurrence in a xenograft model
of colon cancer. Interestingly, these experiments yielded evidence
of an interconversion between LGR5+ and LGR5− CSCs that
drove tumor regrowth after treatment with the ADC.
Another group has described the generation and testing of
two other anti-LGR5 ADCs (44). The first is composed of a
humanized anti-LGR5 mAb conjugated to MMAE through a
cleavable valine-citrulline linker, via the cysteines that normally
form the interchain disulfides of the mAb. Thus, this conjugate is
very similar to the one described by Gong et al. (43). The second
conjugate, NMS818, is composed of the same mAb connected,
via an engineered cysteine on the antibody heavy chain and an
acid-sensitive linker, to the C-14 hydroxyl of the DNA-binding,
topoisomerase-inhibiting anthracycline PNU159682.
In vivo experiments showed the ADC anti-LGR5-MMAE to be
efficacious without affecting homeostatic epithelia or any other
tissues known to express LGR5. On the other hand, the ADC
NMS818 showed target-dependent toxicities consistent with the
known expression patterns of LGR5. The lack of gut toxicity
with anti-LGR5-MMAE may possibly be due to the fact that
the elimination of intestinal LGR5+ cells is well-tolerated. On
the other hand, NMS818 target-dependent toxicity observed in
the intestine may be attributable to the combined elimination
of target-expressing LGR5 cells and bystander cells. In fact, both
ADCs release a membrane-permeable drug after internalization
that could exert a bystander effect on neighboring cells. However,
the free drug released from NMS818 is 10- to 100-fold more
potent on dividing cells, including normal LGR5+ cells, than
MMAE. This could explain the greater toxicity of anti-NMS818
than anti-LGR5-MMAE.
Antitumor efficacy was observed both in xenografts as well
as in genetically engineered mouse models of colon cancer,
and both in tumors with uniformly high expression of LGR5
as well in tumors with heterogeneous and low expression of
LGR5, the latter reflecting more closely the situation found
in human tumors. Importantly, changes in tumor size were
not immediately apparent, but became evident with long-term
treatment, suggesting that depletion of CSCs takes longer to
manifest as compared to the targeting of non-CSCs.
While there are clinical trials ongoing with amonospecific and
a bispecific anti-LGR5 mAb, no trials are currently reported with
one of the ADCs described here.
Antitumor ADCs That Were Shown to Have
Anti-CSC Activity at a Later Stage
Anti-human Epidermal Growth Factor Receptor 2
(HER2) ADC
HER2 is a transmembrane receptor tyrosine kinase that mediates
several functions like growth, differentiation and survival in
malignant and normal breast epithelial cells. Breast cancers
overexpressing HER2 have an aggressive clinical phenotype,
increased disease recurrence and unfavorable prognosis.
Moreover, HER2 is overexpressed on breast CSCs, even on those
subtypes that are not classified as HER2+ (74).
HER2 is the target of two antibody-based compounds that
have gained approval: the first if the mAb trastuzumab (75),
the second is the ADC ado-trastuzumab emtansine, which is
composed of trastuzumab conjugated through a non-cleavable
linker to the antimitotic drug maytansine DM1 (27). Clinical
use of these compounds is for HER2+ breast cancer, with HER2
overexpression on the bulk of tumor cells, independently of their
co-expression on CSCs.
The knowledge that CSCs overexpress HER2, whether or not
the bulk of tumor cells are HER2+, led to investigate the effect
of T-DM1 on CSCs (45). For this purpose, primary tumor cells
and breast cancer cell lines were treated with T-DM1. The results
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showed that breast CSCs with the CD44highCD24lowHER2low
phenotype were very efficient in internalizing T-DM1 and
highly sensitive to it. This caused the depletion of breast
CSCs at concentrations of T-DM1 that did not affect the
bulk of tumor cells. Moreover, colony formation was also
efficiently suppressed and EMT-mediated induction of stem
cell-like properties was prevented in differentiated tumor cells.
Importantly, the unconjugated antibody, trastuzumab, did not
have these effects, pointing to a direct effect of the payload-
induced cytotoxicity in depleting CSCs.
Anti-CD33 ADC
Gemtuzumab ozogamicin (GO) is an anti-CD33 ADC composed
of a humanized anti-CD33 mAb linked to the cytotoxin
calicheamicin via a hydrazone linker. GO has a tormented
history. It received US Food and Drug Administration approval
in 2000 for CD33+ AML, but was voluntarily withdrawn in
2010 due to safety concerns. Later, in a meta-analysis of patient
data from clinical trials, it was found that the combination of
lower-dose GO and induction chemotherapy reduced the risk
of relapse and improved the relapse-free survival and overall
survival in adult AML patients with favorable cytogenetics (76).
These results led, recently, to the reapproval of GO.
Induction chemotherapy based on daunorubicin and
cytarabine was investigated in combination with GO in patient-
derived xenograft AML models (46). The separate treatments
reduced AML burden but left significant chemoresidual
disease. Chemoresistant cells displayed markers of LSCs and
showed greater ability to self-renewal than bulk leukemic cells.
Interestingly, CD33 was coexpressed in the chemoresistant
cells. Combination treatment, on the other hand, was
highly effective in eliminating nearly all AML burden,
extended overall survival and more effectively eliminated
chemoresistant LSCs.
Anti-neural Cell Adhesion Molecule (NCAM, CD56)
ADC
Wilms’ tumor is the most frequent tumor of the genitourinary
tract in children. It displays a triphasic histology: cell lineages
similar to those observed during kidney development,
undifferentiated blastema and stromal and epithelial derivatives
(e.g., immature tubules and glomeruloid bodies). Evidence for
the existence of CSCs in human Wilms’ tumor was obtained
in in vitro cultures derived from primary tumors. In these
experiments it was found that NCAM+ cells of blastema
phenotype had enhanced capacity to expand and differentiate
into mature renal-like cell types, showing that they were greatly
enriched for CSCs (77). They could be further enriched by
aldehyde dehydrogenase activity and overexpression of other
stemness genes and showed preferential expression of Akt
and strong reduction of the miR-200 family, a miRNA family
involved in the down-regulation of EMT and maintenance of an
epithelial phenotype (78).
In order deplete NCAM+ cells in Wilms’ tumors an ADC
was used that had already been constructed and developed,
lovortuzumab mertansine (47). This ADC is composed of
a humanized anti-NCAM mAb, lovortuzumab, linked via a
cleavable disulfide linker to the maytansinoid DM1, mertansine.
In vitro, it inhibited the stemness properties of Wilms’ tumor
cell cultures that varied in the extent of NCAM expression.
Results suggested also that EMT promoted the acquisition of
a CSC phenotype generating highly tumorigenic cancer cells
with a mesenchymal phenotype. In vivo, the ADC eradicated,
at low doses, Wilms’ tumors bearing high NCAM expression,
while higher doses were required for Wilms’ tumors with lower
NCAM expression.
The clinical development of this ADC has recently been halted
due to disappointing results in a clinical study in lung cancer
patients (48).
A CRITICAL APPRAISAL OF ANTI-CSC
ADCS
ADCs against CSCs, similarly to other anti-CSC compounds,
have raised considerable hopes as regards their therapeutic
efficacy. Recently, however, one of the most advanced ADCs
of this class, the anti-DLL3 ADC rovalpituzumab tesirine, has
yielded disappointing results in a clinical trial (NCT02674568)
in patients with SCLC (30). This is despite encouraging results
in an initial phase I clinical trial in the same indication (79).
This failure parallels other pitfalls with drug candidates targeting
CSCs, including other ADCs. The question now arises whether
these approaches, including the ADC approach against CSCs,
have entered a dead-end street or if there is room for envisioning
a new start based on a better understanding of the reasons
underlying these failures. In the following we will list some of the
reasons that appear to us as the most likely ones.
The first aspect relates to the biology of CSCs. CSCs are
themselves a heterogeneous population that can be grossly
divided in two subpopulations: a proliferating and a quiescent
subpopulation. There are strong indications that the quiescent
subpopulation is in an autophagic state (67). Importantly,
there are also evidences that these two subpopulations may
occupy different niches within tumor tissues (80). The location
of a tumor cell within a tumor is crucially important for
their sensitivity to drugs, including antibodies and ADCs
(81). This implies that, depending on their location, different
CSC subpopulations may be differently sensitive to the
same drug.
The existence of proliferating and quiescent CSC
subpopulations implies also that ADCs carrying cell cycle-
independent drugs like DNA binders have an advantage over
cell cycle-dependent drugs like tubulin binders and may lead
to a more complete elimination of CSCs because of their
potential to delete both proliferating as well as quiescent cells. If,
however, quiescent CSCs are in an autophagic state, and there is
considerable evidence in favor of this possibility (reviewed in 40),
then there is another dark side that we should consider because
our knowledge on this aspect and the possible consequences is
almost nil. In fact, we don’t know whether the internalization
and intracellular trafficking in autophagic cells follows the same
kinetics and routes as that of the non-autophagic counterparts.
Recent evidence suggests, indeed, that there are differences (82).
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This implies that these differences may cause in autophagic
CSCs to a release of the active drug that is less efficient that in
proliferating CSCs.
Another limitation of the ADCs that are currently developed
is that none of them targets a marker that is strictly CSC-specific.
As already discussed before, these targets are also expressed,
albeit to a lesser degree, on the bulk of tumor cells. This is
notwithstanding the lack of reactivity of these ADCs for normal
stem cells and the lack or limited reactivity for normal tissues.
At this point one is led to ask whether these ADCs are truly
anti-CSC ADCs or anti-tumor cell ADCs that embrace a tumor
cell population that includes also CSCs. This is not necessarily a
disadvantage, but then one has to evaluate the overall antitumor
activity of the ADC in order to predict its efficacy and not just the
anti-CSC activity.
One of the most important, yet disregarded aspects of
CSC biology lies in the capacity of CSCs and non-CSCs to
interconvert. This aspect has already been briefly addressed in
the first section of this article. Nevertheless, it is important, at
this point, to underscore the consequences that this may have
on the whole tumor cell population and on CSCs. We have
discussed that the conversion from non-CSC to CSCs can be
driven by stressors in the tumor microenvironment, including
hypoxia, mechanical stress, chemotherapy etc. These stressors
may show inter- and even intratumoral variability depending
on the geographical conditions of the tumor microenvironment.
This implies that the fraction of CSCs may greatly vary from one
tumor to the other and even within individual tumors. Such great
variability has been documented in several instances (83, 84) and,
in some cases, one out of four tumor cells have been shown to
display properties of CSCs (85). It is clear that in these cases the
boundaries between non-CSCs and CSCs become very blurred.
The capacity of CSCs and non-CSCs to interconvert represents
a substantial difference compared to normal stem cells. In fact,
normal stem cells reside at the top of a pyramid where they can
self-renew or give rise to a more differentiated progeny (86). This
implies a unidirectional process, whereas the capacity of CSCs
and non-CSCs to interconvert implies a bidirectional process.
This raises serious doubts as to the appropriateness to refer to
these cells as stem cells. Perhaps a definition like “resistant cancer
cells” would be more appropriate to portray the essential of
these cells.
Last but not least, an important limitation in the development
of antibodies and ADCs is represented by the animal models
that are used for preclinical testing. As can be seen just going
through the articles that are referenced here, it is rather quite
common that the compounds tested in animal models lead to
complete tumor regressions, yet the same compounds fail in the
human setting (e.g., 31, i.e., the ADC rovalpituzumab tesirine).
In other terms, the predictability of animal models is very limited
and it seems appropriate to say that observing complete tumor
regressions in animal models is, nowadays, a necessary but by far
not sufficient condition. At this point, the obvious question arises
as to why animal (essentially mouse) models are inadequate to
predict efficacy of antibodies and ADCs? A detailed discussion
of this aspect goes beyond the scope of this article. Nevertheless,
we would like to briefly address two aspects that may contribute
to this insufficiency. First, the percentage of injected dose of
an antibody or antibody-like construct that is taken up by the
tumor mass (expressed in grams) is much lower for humans
than for mice (87). This is because an antibody dose diluted in
a larger plasma volume gives a much lower percentage of injected
dose/gram tumor tissue, three orders of magnitude lower for
humans (∼3 l plasma volume) than mice (∼2ml). Such a dose
may be sufficient to eradicate a tumor in a mouse, but insufficient
to eradicate an equivalent tumor in a human. Incidentally, it
has been recently demonstrated that the intratumoral payload
concentration correlates with the antitumor activity of ADCs
(88), a result that underscores the importance of attaining a
sufficient antibody or ADC concentration within a tumor tissue
in order to be efficacious. The second aspect relates to the
mouse tumor models that are commonly used to test antitumor
drugs, including those that are considered mimicking most
closely the human situation, PDXs. It seems very difficult that
these models can fully mimic the heterogeneity encountered
in the human setting, in particular as regards the possibility
that stressors from the tumor microenvironment may induce a
conversion of non-CSC to CSCs. Thus, in one of the articles
that have been referenced here (41), the anti-5T4 ADC MEDI-
0641 ablated CSCs in one PDX model of HNSCC, reduced the
frequency of CSCs 5-fold in a second PDX model, and 2-fold
in a third PDX model (M11). Yet, in spite of the relatively
modest CSC reduction that was observed in the M11 model,
MEDI-0641 was able to completely prevent tumor recurrence
after surgical removal of the tumor in this model. This leads
obviously to ask as to which is the predictability of ADC-induced
reduction of CSC frequency on the in vivo efficacy of an ADC
in PDX models.
In spite of all these limitations and even if we resort to
a minimalist definition of CSCs as tumor cells that become
drug-resistant in response to stressors generated in the tumor
microenvironment, then we have to agree that it remains a
desirable therapeutic goal to get rid of these cells together with the
rest of the tumor cells, i.e., the proliferating, drug-sensitive tumor
cells. The point is to how best attack these cells. Addressing this
question, however, implies recapitulating all of the limitations
that we have listed and discussed in the first part of this section.
Now, how can we address this conundrum? There is no easy
answer to this but, at present, we can envisage two possibilities
that can to be implemented.
The first of these possibilities is to develop in silico models of
human tumors that are better able to predict efficacy of antibodies
or ADCs than do the present animal models. Efforts in this
direction are ongoing (89). Thus, in silico models for tumor
growth and tumor treatment have been described (90, 91). In
perspective, it seems reasonable to predict that these models
may incorporate a number of variables allowing them to match
the situation(s) encountered in the human setting more closely
than currently used animal models, including PDX models, are
able to do.
Second, the identification of biomarkers that are predictive
of clinical efficacy of anti-CSC ADCs, similarly to the
overexpression of HER2 that is used to predict efficacy of
trastuzumab in HER2+ breast cancer patients. Biomarkers,
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including circulating tumor cells (CTC), witnessing antitumor
effects in general and anti-CSC effects in particular (e.g.,
CTCs with a mesenchymal phenotype or soluble markers from
mesenchymal CSCs), may allow to predict in a more reliable
manner the overall clinical efficacy of anti-CSC ADCs. Such an
approach could be systemically applied to the anti-CSC ADCs
that are currently in clinical development. Elucidation of the
relationship/lack of relationship between anti-CSC activity and
clinical efficacy could allow to identify the contribution of anti-
CSC activity to the overall antitumor activity and predict the
efficacy of novel ADCs.
Overall, the present scenario regarding the clinical efficacy
of anti-CSC ADCs is not very encouraging, yet the biological
functions of CSCs suggest that further efforts should be devoted
to this goal. Here, we have proposed some activities that could
help moving forward in this field.
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